ImCheck Therapeutics

ImCheck Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapeutics targeting members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. The company's lead product candidate, ICT01, is a humanized, anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, a subpopulation of killer lymphocytes that play a key role in anti-tumor and anti-infective responses. ICT01 is currently in a Phase I/IIa clinical trial program in various solid cancer and hematologic malignancy indications. ImCheck also has a second product candidate, ICT41, which is a humanized, anti-BTN3A monoclonal antibody targeting γ9δ2 T cells for the treatment of infectious diseases.

ImCheck has gained significant funding from a syndicate of leading international life science investors, including a recent EUR 96 million (USD 103 million) financing round. The company is headquartered in Marseille, France, and has a team of experienced scientists and clinicians dedicated to developing novel immunotherapies with the potential to improve patient outcomes. ImCheck's unique approach to immune modulation has the potential to revolutionize the treatment of cancer, infectious diseases, and autoimmune diseases.

ImCheck Therapeutics is a biotechnology company focused on developing innovative immunotherapies that target the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. The company's mission is to design and develop novel antibodies that modulate the immune system for the treatment of a range of diseases, including cancer, infectious diseases, and autoimmune diseases. ImCheck's approach is rooted in its deep understanding of the BTN/BTNL family, particularly its ability to activate gamma delta (γ9δ2) T cells, a powerful subset of immune cells that play a critical role in anti-tumor and anti-infective responses.

ImCheck Therapeutics fosters a dynamic and collaborative work environment where innovation and scientific excellence are valued. They encourage a culture of continuous learning, challenging work, and personal growth, all while striving to make a positive impact on patients' lives.